Related Experiment Video
Updated: Aug 21, 2026

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
Published on: September 20, 2024
Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience
Scott G Houghton1, David R Farley, Michael D Brennan
1Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Insights
Thyroidectomy offers an effective treatment for amiodarone-associated thyrotoxicosis (AAT), particularly when medical management fails. However, this surgical approach carries significant risks, including perioperative complications and mortality, especially in patients with underlying cardiac conditions.
Area of Science:
- Endocrinology
- Cardiology
- Surgical Oncology
Background:
- Amiodarone-associated thyrotoxicosis (AAT) presents challenges due to underlying cardiac disease and resistance to medical therapy.
- Surgical intervention is considered for AAT patients refractory to or intolerant of medical management, or those requiring continued amiodarone therapy.
Observation:
- A retrospective review of 34 patients (29 men, 5 women; median age 60) undergoing thyroidectomy for AAT between 1985 and 2002.
- Common symptoms included worsening heart failure, fatigue, weight loss, and tremor. Indications for surgery included medically refractory disease, cardiac decompensation, and severe symptoms.
- The median American Society of Anesthesiologists (ASA) classification was 3, indicating significant comorbidity.
Findings:
- Thyroidectomy was performed on patients with AAT, with 12 failing prior medical management and 21 receiving no preoperative therapy.
- Histology confirmed AAT in 27 specimens. Complications included mortality (n=3), rehospitalization (n=3), symptomatic hypocalcemia (n=2), and other serious events.
- Of 31 survivors, 80% continued amiodarone post-surgery. At a median follow-up of 29 months, all survivors were free of hyperthyroid symptoms.
Implications:
- Thyroidectomy is an effective treatment for amiodarone-associated thyrotoxicosis, achieving symptom resolution.
- The high rate of perioperative morbidity and mortality highlights the risks associated with this procedure in a high-risk patient population.
- Careful patient selection and risk assessment are crucial for managing AAT surgically, considering the significant cardiovascular comorbidities.
Abstract:
Amiodarone-associated thyrotoxicosis (AAT) is often poorly tolerated owing to underlying cardiac disease, and it is frequently refractory to conventional medical treatment. The goal of this study was to describe the patient characteristics, management, and outcomes of all the patients treated surgically for AAT at a single institution. We conducted a retrospective chart review of all patients managed surgically for AAT (April 1985 through November 2002) at the Mayo Clinic in Rochester, Minnesota. Altogether, 29 men and 5 women, ages 39 to 85 years (median 60 years), treated with amiodarone for 3 to 108 months underwent near-total or total thyroidectomy. Frequent symptoms were worsening heart failure, fatigue, weight loss, and tremor. Altogether, 12 patients failed medical management of their AAT, and 21 received no preoperative medical therapy. One patient had been successfully managed medically but required definitive treatment. Common indications for operation were the need to remain on amiodarone, cardiac decompensation, medically refractory disease, and severe symptoms, both hyperthyroid and cardiac, necessitating prompt resolution. The median+/-SD American Society of Anesthesiologists (ASA) classification (1 = healthy through 5 = moribund) was 3.00+/-0.58. A total of 27 specimens had histology consistent with AAT. Complications included death (n = 3), rehospitalization (n = 3), symptomatic hypocalcemia (n = 2), pneumonia (n = 2), cervical hematoma (n = 1), prolonged ventilatorywean (n = 1), and stroke (n = 1); one patient developed hypotension, adult respiratory distress syndrome, and sepsis. Of the 31 surviving patients, 25 (80%) remained on amiodarone postoperatively. The median follow-up was 29 months, at which time all surviving patients were free of hyperthyroid symptoms. Thyroidectomy is an effective treatment for AAT but has a high incidence of perioperative morbidity and mortality. The cardiovascular co-morbidities and high operative risk in this group of patients may account for the increased complication rate.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Myocarditis III: Medical Management
Mitral Stenosis III: Medical Management
Hyperthyroidism II: Pathophysiology
Hyperthyroidism I: Introduction
Mitral Regurgitation III: Medical Management
